Denali Therapeutics Priced, Nasdaq: DNLI

An early-stage biotech developing novel therapies for neurodegenerative diseases.

Industry: Health Care

Latest Trade: $20.04 0.00 (0.0%)

First Day Return: +19.2%

Return from IPO: +11.3%

Industry: Health Care

Our goal is to discover and develop therapeutics to defeat degeneration. We have a focused yet diversified portfolio that currently consists of six core and five seed programs. Our most advanced program targets LRRK2 for the treatment of Parkinson's disease and has a product candidate currently in Phase 1 development. Our next most advanced program targets RIPK1 for the treatment of Alzheimer's disease and ALS and current has a product candidate in IND-enabling studies with an IND or CTA filing planned for early 2018. In addition, we have four core programs in preclinical development that use our proprietary blood-brain barrier (BBB) platform technology.
more less
IPO News for Denali Therapeutics
more
IPO Data
IPO File Date 11/13/2017
Offer Price $18.00
Price Range $17.00 - $19.00
Offer Shares (mm) 13.9
Deal Size ($mm) $250
IPO Data
IPO Date 12/07/2017
Offer Price $18.00
Price Range $17.00 - $19.00
Offer Shares (mm) 13.9
Deal Size ($mm) $250
Underwriters
more
Company Data
Headquarters San Francisco, CA
Founded 2015
Employees 125
Website www.denalitherapeutics.com